NEOS-223 / NeoSome Life Sci - LARVOL DELTA

Selective inhibition of NRAS-GTP in cancer models with small molecule NEOS-223 (AACR 2025) - "NEOS-223 has a greater synergistic effect on inhibition of cell proliferation combined with specific targeted inhibitors such as gefitinib (EGFR), sotorasib (KRAS G12C), vemurafenib (BRAF V600E) and MRTX1133 (KRAS G12D) correlating with stronger suppression of EGFR-RAS-MAPK signaling. Our study highlights the feasibility of developing NRAS selective inhibitor for therapeutic efforts and these results suggest that NRAS plus KRAS to be a promising strategy for treating both EGFR and RAS mutant tumors. Overall, these data provide important mechanistic insight to guide therapeutic strategies targeting NRAS mutant, dependent and resistance tumors."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • HRAS • KRAS • NRAS

NEOS-223 is a small molecule kinase inhibitor which induces apoptosis in selected cancer models (AACR 2024) - "Most importantly, in vivo data showed that while administration of NEOS-223 alone decreased tumor growth, the addition of PI3K/Akt/mTOR inhibitor onatasertib significantly enhanced anticancer effect in a lung cancer model. In lung and pancreatic cancer models, inhibition of EGFR by the small molecule drug gefitinib strongly showed synergistic effect with NEOS-223 both in vitro and in vivo. This may be because EGFR potentially activates both the mitogen activated protein kinase (MAPK/ERK) and the PI3K/mTOR signaling cascades in different mutant cancer models. These studies reveal that NEOS-223 inhibits cell proliferation and induces apoptosis via suppressing the PI3K/Akt/mTOR pathway and further suggest that the combination of PI3K/Akt/mTOR and EGFR inhibitors and that NEOS-223 would be a strong potential chemotherapeutic strategy against lung and pancreatic cancers."

Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • BRAF